Bone Therapeutics IPO raises 32.2 million euros
Belgian cell therapy specialist Bone Therapeutics has raised 32.2 million euros in a heavily-oversubscribed initial public offering.
Read MoreAuthor: Kevin Grogan
Genmab multiple myeloma drug shines in Phase II
Genmab and partner Johnson & Johnson have been boosted by positive mid-stage data on daratumumab for multiple myeloma.
Read MoreGilead profits rocket but HCV drugs discounts will hurt
Sales of Gilead Sciences’ two hepatitis C blockbusters – Sovaldi and Harvoni – have sent the firm’s fourth-quarter profits soaring four-fold, though its shares took a hit over the disclosure that 2015 revenues will be hurt by deep discounts in the USA.
Read MoreGSK hopes for happier times as earnings fall
GlaxoSmithKline has ended a disappointing year with another set of mediocre figures for the fourth quarter but the drugs giant is hopeful it is on the right track.
Read MoreMerck & Co profit soars but hep C combo ‘not breakthrough’
Merck & Co’s huge rise in profits was overshadowed somewhat by the news that the US Food and Drug Administration will rescind breakthrough therapy designation for its hepatitis C combo, due to the highly-effective drugs from Gilead Sciences and AbbVie already on the market.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
